ATLAS and FLAIR were clinical trials designed to evaluate the efficacy and safety of long-acting CABENUVA in adult (≥18 years) patients with HIV-1 who were virologically suppressed at time of randomization. 3 The primary endpoint for both studies was the proportion of patients with HIV-1 RNA ≥50 copies/mL at Week 48. 1,2

Explore ATLAS-2M efficacy and safety data, including study design and baseline characteristics for the CABENUVA (cabotegravir; rilpivirine) study. For US HCPs only. Learn more about the study design and efficacy data from the every-2-month trial for CABENUVA.

Atlas all-terrain vehicle - Versatility, Passage, Ease of Management, Maneuverability. Order an all-terrain vehicle from the manufacturer at the best prices +38 073 009-9-000

Advances in antiretroviral (ARV) treatment and a better understanding of HIV drug resistance have made it possible to consider switching a person with HIV from an effective ARV regimen to an alternative ARV regimen in some situations.

Mar 4, 2020 · Here we report the 48-week (primary end point) results of the phase 3 Antiretroviral Therapy as Long Acting Suppression (ATLAS) trial, the purpose of which was to establish whether switching to...

48-week data from the Phase III ATLAS study and FLAIR study, demonstrating Cabenuva’s safety and efficacy as maintenance therapy with intramuscular dosing every four weeks, have been published in the New England Journal of Medicine.

Dec 19, 2020 · Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Feb 18, 2021 · Two Phase 3 trials (ATLAS and FLAIR) that enrolled almost 1,200 participants with HIV evaluated the safety and efficacy of once-monthly IM injections of CAB and RPV. Individuals with active HBV infection or who were pregnant were excluded from both trials.

ATLAS-2M is a multicenter, Phase 3b, randomized, open-label study investigating cabotegravir + rilpivirine long- acting (CAB + RPV LA) dosed every 8 weeks (Q8W) and every 4 weeks (Q4W) as a maintenance regimen for people living with HIV-1.

Jan 1, 2015 · In April 2019, the U.S. Food and Drug Administration approved a combination pill comprising the integrase inhibitor dolutegravir (DTG), 50 mg, and the NRTI lamivudine (3TC), 300 mg, for use as a complete ARV regimen for initial HIV treatment of patients.